Page 9 - Aduhelm News Today

Confirmatory trial's completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of diverse

WESTON (dpa-AFX) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug Administration

A drug to prevent preterm birth may provide the next test of the agency’s process for speedily getting drugs on the market, despite limited evidence that some work.

WASHINGTON (AP) — When patients are battling a terminal illness and want access to an...

Aduhelm maker Biogen has set up a data network to track how neurological disease medicines perform in the real world after clinical trials.

Eisai has decided to exit its supporting role for Biogen's Alzheimer's drug Aduhelm. Chinese companies including several biotechs face potential U.S.

WESTON (dpa-AFX) - Biogen Inc. (BIIB) said new data showed that after nearly two and a half years of treatment (128 weeks) with ADUHELM injection 100 mg/mL for intravenous use, patients in the

ADUHELM continued to reduce two key Alzheimer's disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half yearsData from both Phase 3 studies also show that clinical

By Michael Dabaie Biogen Inc. unveiled new data showing that after nearly two and a half years of treatment Aduhelm continues to reduce underlying pathologies of Alzheimers disease. ... | March 16, 2022

CAMBRIDGE, Mass., March 16, 2022(Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer's Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3